Pulnovo Medical Raises $100 Million to Advance Pulmonary Hypertension Therapies

Pulnovo Medical, a company specializing in medical technologies for pulmonary hypertension and heart failure, has announced a significant funding milestone. On April 20, 2026, the company completed a $100 million funding round led by Medtronic. The round also saw participation from existing investors such as EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures, along with new investor HSG.

Strategic Funding Round

The funding round, which was not disclosed as a specific series, marks an important step for Pulnovo Medical as it aims to expand its global reach and further validate its technology. The investment will bolster the company's efforts in clinical development and regulatory submissions worldwide.

Use of Funds

Pulnovo Medical plans to allocate the new funds to several key areas:

  • Clinical Development: The company will continue to advance its clinical trials, including those in the United States where it has secured FDA Breakthrough Device designation.
  • Global Regulatory Submissions: Efforts will be intensified to obtain approvals in more regions, building on existing regulatory successes in seven countries.
  • International Commercialization: Pulnovo will expand its commercialization activities across the European Union, Middle East, and China.
  • Technology Platform Investment: Further investment in Pulnovo's core technology, particularly its Pulmonary Artery Denervation (PADN) System, which has already been utilized in approximately 1,500 procedures globally.

Leadership and Strategic Partnerships

Cynthia Chen, the founder of Pulnovo Medical, continues to lead the company through this new phase of growth. In addition to the funding, Pulnovo Medical has entered a commercial agreement with Medtronic to explore future opportunities leveraging Medtronic’s global infrastructure.

The company has also strengthened its leadership team by appointing Andre Xiao as Chief Strategy Officer. Xiao brings valuable experience from his previous roles in MedTech investments, and he will oversee global financing and strategic initiatives.

Conclusion

Pulnovo Medical's recent funding round underscores its commitment to advancing therapies for pulmonary hypertension and heart failure. With the backing of major investors and strategic partnerships in place, the company is well-positioned to make significant strides in its clinical and commercial endeavors.